Singapore based HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced a strategic partnership with Houston Research Institute (HRI). HRI is a leading research institute focused on conducting clinical trials in hepatology and gastroenterology, with a special emphasis on metabolic liver disease. The institute delivers high-quality research that complements the medical care that volunteers receive through their routine care centre.
This collaboration represents a key step in HistoIndex's growing network of commercial partnerships with hepatology and gastroenterology medical centers across the United States and Europe. Through these partnerships the company will provide advanced diagnostic testing services to patients with Metabolic Dysfunction–associated Steatohepatitis (MASH), supporting more precise disease assessment and clinical decision-making.
Under the partnership, all four HRI medical centers - Houston Research Institute Pasadena, Houston Research Institute Sugar Land, Houston Research Institute, and Houston Research Institute Medical Center - will have access to HistoIndex's integrated diagnostic offering, which combines expert histopathological evaluation by experienced pathologists with advanced AI-based biopsy analysis.
To complement standard-of-care histological evaluation of MASH, for steatosis, lobular inflammation, ballooning and fibrosis, HistoIndex will also offer its proprietary AI-based diagnostic test, FibroSIGHT™ Plus, which delivers fully quantitative assessment of liver fibrosis in MASH liver biopsies.
From the clinical perspective, the collaboration enhances diagnostic capabilities across HRI's centres.
The collaboration between HistoIndex and HRI reflects a shared commitment to bringing combined expert histopathology and AI-based fibrosis analysis to MASH patients across the US.
